Selected papers (2009)
Gomez JM, Vilarrasa N, Masdevall C, Pujol J, Solano E, Soler J, Elio I, Gallart L, Vendrell J. Regulation of Bone Mineral Density in Morbidly Obese Women: A Cross-sectional Study in Two Cohorts Before and After Bypass Surgery. Obesity Surgery. 2009;19(3):345-50.
Vilarrasa N, Gómez JM, Elio I, Gómez –Vaquero C, Masdevall c, Pujol J, Virgili n, Burgos R, Sánchez-Santos R, de Gordejuela AG, Soler J. Evaluation of bone disease in morbidly obese women after gastric bypass and risk fcators implicated in bone loss. Obes Surg 2009;19(7):860-6
Montanya E, Sesti G. Liraglutide. The once-daily human GLP-1 analogue. Clinical Therapeutics 2009;31(11)
Ceperuelo-Mallafré V , S Näf, X Escoté, E Caubet, JM Gómez, M Miranda, MR Chacón, JM González-Clemente, L Gallart, C Gutiérrez, J Vendrell. Circulating and adipose tissue gene expression 1 of zinc-alpha2-2 glycoprotein in obesity. Its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat. J Clin Endocr Metab. 2009; 94: 5062-5069.
Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
